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Abstract
Background: Hepatitis C (HCV) is a deleterious virus that can be cured with new, highly effective anti-viral treatments,
yet more than 185 million individuals worldwide remain HCV positive (with the vast majority un-diagnosed or
untreated). Of importance, HCV is a leading cause of chronic liver disease and liver cancer, especially in Sub-Saharan
Africa (SSA) where the prevalence remains high but uncertain due to little population-based evidence of the epidemic.
We aimed to synthesize available data to calculate and highlight the HCV disease burden in SSA.
Methods: Weighted random-effects generalized linear mixed models were used to estimate prevalence by risk cohort,
African region (Southern, Eastern, Western, and Central Africa), type of assay used, publication year, and whether the
estimate included children. A pooled prevalence estimate was also calculated. Multi-variable analyses were limited to
cohort and region specific prevalence estimates in the adult population due to limited studies including children.
Prevalence estimates were additionally weighted using the known adult population size within each region.
Results: We included more than 10 years of data. Almost half of the studies on HCV prevalence in SSA were from the
Western region (49 %), and over half of all studies were from either blood donor (25 %) or general population cohorts
(31 %). In uni-variable analyses, prevalence was lowest in Southern Africa (0.72 %), followed by Eastern Africa at 3.00 %,
Western Africa at 4.14 %, and Central Africa at 7.82 %. Blood donors consistently had the lowest prevalence
(1.78 %), followed by pregnant women (2.51 %), individuals with comorbid HIV (3.57 %), individuals from the general
population (5.41 %), those with a chronic illness (7.99 %), and those at high risk for infection (10.18 %). After adjusting
for the population size in each region, the overall adult prevalence of HCV in SSA rose from 3.82 to 3.94 %.
Conclusion: This meta-analysis offers a timely update to the HCV disease burden in SSA and offers additional evidence
of the burgeoning epidemic. The study highlights the need to account for type of cohort and region variation when
describing the HCV epidemic in SSA, the need for more studies that include children, as well as the need to factor in
such variations when planning public health interventions.
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Background
Hepatitis C Virus (HCV) is a leading cause of chronic
liver disease, cirrhosis, and liver cancer worldwide and is
a primary indication for liver transplantation [1]. With
no available vaccine, treatment and disease prevention
remain the primary methods to reduce disease burden.
Fortunately, new highly active anti-viral agents provide
the opportunity to cure diagnosed and treated individuals
[2]. As such, a renewed interest in estimating the global
disease burden of this deadly infection is both timely and
necessary.
Significant discrepancies exist in recent HCV global bur-
den estimates. Mohd Hanafiah et al. [3] estimated >185
million individuals worldwide were HCV antibody positive
(sero-positive) in 2005, a 52 % increase from 1990 and,
recently, Gower et al. (2014) estimated 115 million
individuals world-wide were sero-positive, noting more
than 80 million individuals expressed viremic infection
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[4]. Discrepancies in these estimates are partially due to ap-
plied inclusion and exclusion criteria, particularly whether
estimates were derived using blood donors and minors as
well as the time periods that capture available data.
Despite these differences, both studies reveal that
Sub-Saharan Africa (SSA) suffers from an alarming
HCV disease burden. Our true understanding of the epi-
demic in SSA is unfortunately profoundly limited by a lack
of robust primary data, including limited population-
based studies [4]. As such, there is significant uncertainty
when estimating the true disease burden in SSA. A recent
meta-analysis revealed a pooled HCV sero-prevalence of
2.98 % across SSA [5], and studies have identified signifi-
cant variability across geographic region (i.e., Central,
Southeastern, and Western Africa) and risk group (e.g.,
blood donors, pregnant women, those with an existing
liver disease, substance users, etc.) [3, 5]. Such variation
suggests an overall disease burden estimate may not be
appropriate for SSA. Previous work also suggests that the
serologic assay used to determine HCV status may impact
prevalence estimates due to variation in false positivity
rates [6–8]. Further, it is speculated that children have
lower overall disease burden, and estimates that include
or exclude children vary considerably in previously
reported estimates [9]. Consequently, it is important for
prevalence estimates to account for geographic region of
SSA, study population, year of study, and diagnostic assay
used, because these parameters may greatly impact disease
estimates. Rarely have studies adjusted prevalence
estimates to account for these effect modifiers, nor have
studies attempted to adjust estimates based on the com-
position of the population in general.
The primary aim of this study was to conduct a meta-
analysis on the HCV sero-prevalence in SSA, examining
the impact of region, cohort, year of study, and diagnos-
tic assay used to generate the estimates. A secondary
aim used the model based cohort estimates to derive a




This study adhered to the meta-analysis of observational
studies (MOOSE) guidelines established in 2008 [10].
Articles and abstracts were identified for this meta-
analysis by searching the following academic search
engines: (1) Medline, (2) Ovid, (3) EMBASE, (4) Google
Scholar, (5) PubMed, and (6) Academic Search
Complete/EBSCO using keywords (a) “Hepatitis C AND
Sub-Saharan Africa”, (b) “HCV AND central Africa”, (c)
“HCV AND eastern Africa”, (d) “HCV AND western
Africa”, (e) “HCV AND southern Africa” and (f ) “HCV
AND prevalence AND Africa”. When articles or ab-
stracts were identified, snowball sampling was employed
to find additional articles referenced in the published
material.
We limited data capture to articles published from
January 2000 through December 2013 that sampled
from mainland countries in SSA. Only publications
printed in English, Spanish, and French were retained.
Articles without original data or without HCV preva-
lence estimates were excluded.
Data capture
All studies were randomly distributed using a random
numbers table among study team members (NM, NB,
JS, HN, and CS) for double data entry. An electronic query
system flagged discrepancies which two statisticians (SK
and WA) reviewed and resolved. HCV prevalence
estimates and the absolute numbers used to generate such
estimates were recorded for each study. Studies were
grouped into one of four Sub-Saharan regions using
boundaries described by the World Health Organization,
namely Central, Eastern, Western, or Southern Africa
[11]. Publication year, the highest generation diagnostic
assay used (i.e., screening, second, third, or fourth gener-
ation assay), and whether studies enrolled individuals
under age 16 were also recorded.
Each sample was additionally grouped into a population
cohort representing either (1) blood donors, (2) those at
high risk for infection (e.g., studies of prisoners and prison
guards, adults and children with sickle cell disease,
hospital workers, sex workers, intravenous drug users, and
hemodialysis patients), (3) individuals with comorbid HIV
infection, (4) those with a chronic Illness (e.g., individuals
with diabetes, those with a chronic liver disease, or pa-
tients admitted to a healthcare facility), or (5) pregnant
women; studies of household members, adults, outpa-
tients, healthy children, and infants were grouped into a
fifth category representing the general population.
Statistical analyses
All analyses were conducted using SAS software version
9.4, (SAS Institutes, Cary, NC). Prevalence estimates
were weighted using the inverse of the summation of
their between and within study variances (as described
by Hedges and Veva, 1998) [12]. Weighted random-
effects binomial generalized linear mixed models with
logit links were used to estimate prevalence within
population cohorts, SSA regions, type of assay used,
publication year, and inclusion of minors. In these uni-
variable models, each moderator (i.e., population cohort,
region, type of assay used, publication year, and whether
minors were included) represented a fixed effect while
random intercepts were allowed for each study contribut-
ing estimates. To determine a total population prevalence
estimate of Hepatitis C in SSA, an intercept only weighted
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random-effects binomial model was used, allowing for
random intercepts among studies.
Statistical interactions were also assessed using multi-
variable random-effects models. For example, a weighted
binomial random-effects model was used to further as-
sess a significant region-by-cohort interaction. In this
model, region, cohort, and their interaction were fixed
effects while random intercepts were allowed for each
study contributing estimates. Studies that included
minors under age 16 (k = 18) were excluded and, as
such, these multivariable results report Hepatitis C
prevalence estimates only for adults.
We next derived estimates of HCV disease burden that
accounted for adult population sizes within each region.
The 2015 United Nations population database was used
to provide the overall population size in each region for
individuals ≥ 15 years old [13]. The estimated number of
anti-HCV adult individuals per region was calculated by
multiplying each model based region prevalence estimate
by the number of adults within that region. A pooled
prevalence estimate was derived that was weighted by the
population size within each region.
Results
Composition of HCV Sero-prevalence studies in
Sub-Saharan Africa
Of the 361 published articles and abstracts identified for
this analysis 185 articles comprising K = 221 independent
cohorts were retained (i.e., articles were allowed to
contribute multiple independent prevalence estimates -
see Additional file 1: Table S1). Primary reasons for the
exclusion of articles were that they sampled from WHO
defined Northern Africa (k = 69), were printed in a
language other than English, French, or Spanish (k = 15),
had incomplete data (k = 68) or were repeat studies that
engendered dependency (k = 24). See Fig. 1.
Figure 4 displays the number of articles representing
Western Africa populations (K = 107; 48.5 % of all
articles), Eastern Africa (K = 67; 30.3 %), Central Africa
(K = 32; 14.4 %), and Southern Africa (K = 15; 6.8 %)
populations. The distribution of studies by cohort and
region excluding studies that had children is shown in
Fig. 5; studies including children were excluded for this
because subsequent meta-analyses excluded these studies.
Across all regions, the largest proportion of studies report-
ing prevalence estimates occurred among the general
population and blood donors (27.1 % each), followed by
HIV infected individuals (21.7 %). However, there was
dramatic variation in the distribution of cohorts with
prevalence estimates by region, as seen in Fig. 5. For
example, 64.3 % of all studies conducted in Southern
Africa were among HIV infected individuals. In compari-
son, HIV cohorts made up 18.3, 25.4, and 3.8 % of studies,
respectively, in Western, Eastern, and Central Regions.
Uni-variable prevalence estimates
The precision of the prevalence estimates by cohort and
other parameters are shown in Fig. 2. While prevalence
estimates significantly varied across African regions and
cohorts (both p < .001), there was no significant variability
between the inclusion and exclusion of minors (p = .81),
nor by generation of diagnostic assay (p = .63) or
Fig. 1 Article selection and cohort identification
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publication year (p = .73). Prevalence in Southern Africa
was low - estimated at 0.72 % (95 % CI: 0.33–1.54 %). This
was followed by Eastern Africa estimated at 3.00 % (95 %
CI: 2.23–4.02 %) and Western Africa estimated at 4.14 %
(95 % CI: 3.29–5.20 %); Central Africa (7.82 %, 95 % CI:
5.29–11.43 %) had the highest estimated prevalence of
Hepatitis C.
Among the six population cohorts, blood donors had
the lowest prevalence (1.78 %, 95 % CI: 1.31–2.41 %)
followed by pregnant women (2.51 %, 95 % CI: 1.46–4.28),
individuals with HIV (3.57 %, 95 % CI: 2.54–5.00 %) and
those from the general population (5.41 %, 95 % CI: 4.12–
7.08 %). Higher prevalence was observed for both individ-
uals with a chronic illness (7.99 %, 95 % CI: 4.13–14.91 %)
and those considered at high risk for infection (10.18 %,
95 % CI: 6.51–15.59 %).
Multivariable prevalence estimates
Due to the significant interaction of region-by-cohort
(p = .01), a weighted random-effects multivariable
model was used to estimate adult HCV prevalences for
each cohort within its Sub-Saharan region. Because so few
studies had adequate representation of children, and it is
likely that the prevalence of HCV among children is
different but not adequately captured across studies, we
excluded studies that included children for the multi-
variable estimates. Figure 3 displays these adult prevalence
estimates. Blood donor populations consistently had the
lowest adult estimates within each region but varied
across regions, with the highest blood donor prevalence in
Central and Western Africa (2.90 and 2.37 %, respect-
ively). The lowest adult blood donor HCV prevalence was
in Southern Africa with an estimate of 0.02 % (95 % CI:
0.01–0.09 %). Interestingly, outside of the Southern
African region, higher adult prevalence estimates were ob-
served among high risk populations, with the highest
noted in Western Africa (15.69 %; 95 % CI: 9.31–25.22 %).
Across general populations, the highest prevalence was
observed in Central Africa and Southern Africa, with adult
prevalence estimates of 16.26 and 6.40 %, respectively.
However, there was only one study among the general
population in South Africa, making any strong conclu-
sions difficult. In contrast, the lowest general adult popu-
lation estimates were observed in Eastern Africa.
Overall pooled estimates
While the average population prevalence of Hepatitis C
varied significantly across studies (p < .001), it was
possible to account for sampling error as well as
between-studies error using a weighted generalized
linear mixed model with random intercepts. Using this
approach, the overall prevalence of HCV in SSA, when
excluding minors under age 16 was 3.82 % (95 % CI:
3.20–4.55 %); when children were included, the estimate
was similar at 3.80 % (95 % CI: 3.20–4.50 %).
We next derived population estimates that accounted
for the proportion of adults within each region of SSA
(see Additional file 1: Table S1 which provides the
Fig. 2 Univariable seroprevalence estimates of HCV infection by moderator
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adjusted estimates for each region), given that the num-
ber of adults in each SSA region varies. These adjusted
estimates project 21,315,010 adult cases in SSA, with the
greatest proportions occurring in Western and Central
Africa. The overall meta-analysis projected 3.82 % of
adult cases across SSA; conversely, the prevalence
estimate weighted by the proportion of adults within
each region provided a prevalence estimate of 3.94 %.
Discussion
In this study, we examined the sero-prevalence of HCV
across Sub-Saharan Africa. Several key findings resulted
from this study. First and foremost, we found large
variation among studies that have reported on the
sero-prevalence of HCV across SSA and found that
the distribution of cohorts across regions did not
accurately represent SSA as a whole (Figs. 4 and 5).
Nearly half of all studies were conducted in the western
region, and the largest proportions of studies occurred
among blood donors and the general population. The
distribution of cohorts represented in each region was also
highly varied. Further, too few studies report prevalence
estimates among children, limiting the production of
reliable estimates of the sero-prevalence among children.
Secondly, similar to the study by Rao et al. [5], we
found significant variation in HCV prevalence across
SSA regions as well as population cohorts. The highest
prevalence estimates were observed in Central and
Western Africa, with the lowest prevalence noted in
Southern Africa. Blood donors consistently had the
lowest sero-prevalence estimates. Studies among preg-
nant women generally produced lower estimates com-
pared to general population and high risk cohorts. We
tested whether there were significant differences in HCV
prevalence by publication year, diagnostic assay, or
whether children were included in studies and found no
significant variation among these potential modifiers.
Combining this high heterogeneity in the representation
of regions and cohorts in published studies, with the
Fig. 3 Adjusted multivariable adult HCV prevalence for each cohort by region
Fig. 4 Proportion of studies included in meta-analyses by Region
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noted significant variations in sero-prevalence by both
region and cohort, has important implications. First, it
significantly limits the reliability and interpretation of
pooled sero-prevalence estimates, and questions the
usefulness of pooled estimates when describing the HCV
epidemics across SSA. Standard meta-analysis pooled esti-
mates weight by the number of studies and do not readily
account for the distribution of the overall sampling popu-
lation. Blood donor cohort studies make up over a quarter
of all published studies and blood donor derived studies
had the lowest sero-prevalence estimates at 1.78 % overall,
with significant variation by region. Blood donors are
typically younger, more often urban, and male, and prior
studies have shown that they are not always represen-
tative of the overall population [14–16]. In a pooled
meta-analysis approach, however, these estimates carry a
significant weight due to the number of studies and may
provide falsely low estimates. Studies from Western Africa
represent almost half of all studies, and sero-prevalence
estimates from this region are significantly lower than
Eastern Africa, and higher than Southern Africa estimates.
A meta-analysis derived pooled estimate does not import-
antly capture this variation.
Further, comparing these estimates across regions is
profoundly limited due to the heterogeneity of cohorts
represented across regions. For example, Central Africa
had the highest uni-variable sero-prevalence at 7.82 %.
However, 50 % of studies in Central Africa were derived
from general population cohorts that exhibited a high
sero-prevalence of 16.26 %. In Eastern Africa, Western Af-
rica, and Southern Africa, general population cohorts
made up 32, 21 and 7 % of the studies in their region, re-
spectively. One approach would be to adjust or weight for
the proportion of the sampling population that comprises
each cohort in each region. However, there are no stand-
ard populations or accurate estimates identifying the pro-
portion of the overall population comprising each cohort.
At this time, the only plausible weighting would be to con-
sider the population sizes within each region from known
census data. Among adults, our meta-analysis derived
sero-prevalence estimate was 3.82 %. When we weighted
the meta-analysis prevalence estimates by census data,
thus accounting for the number of adults in each region,
the pooled sero-prevalence estimate increased to 3.94 %.
We believe that extreme caution should be used when
interpreting the pooled and weighted estimates, both
Fig. 5 Proportion of studies included in meta-analyses by cohort and region
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because of the heterogeneity in the representation of the
cohorts as well as the varied estimates among cohorts.
However, it does illustrate that weighting estimates can
lead to different, and perhaps, more accurate pooled esti-
mates. In the case of SSA, the inability to weight or adjust
for cohort proportions in and across regions limits the in-
terpretation and accuracy of the estimates.
It is also important to highlight that our pooled
estimate of 3.82 % was among adults only, due to the
limited reported data among children. Adults make up
52 % of the overall population in SSA [13]. Thus, the
total number of HCV cases in SSA is likely higher.
Children, however, are likely to have lower HCV sero-
prevalence estimates. Thus, an overall sero-prevalence,
that includes children, would likely be lower than the
pooled adult prevalence estimate. Studies that sample
among the youth are profoundly lacking but are sorely
needed to help understand the HCV epidemic across
SSA. While there is likely an age cohort effect, such that
the risk of HCV increases with age as has been seen in
other parts of the world, previous work also shows a bi-
modal prevalence peak in younger populations, espe-
cially in Western Africa [3]. Only the conduct of
population-based sampling will allow us an appropriate
understanding of the HCV burden among children
across SSA.
Another key point derived from this study is the need
for careful consideration of cohort classification. We
observed significantly lower sero-prevalence among
blood donors when compared to the general popula-
tions. Rao et al. combined the general population with
blood donors in an overall low risk cohort [5]. This
study emphasizes the need to distinguish estimates from
blood donors and the general population. Further, preg-
nant women generally have lower sero-prevalence esti-
mates than the general population, and thus should be
viewed as a separate cohort. Defining high and low risk
cohorts for HCV risk in SSA is generally difficult, largely
due to the limited data on past and present transmission
pathways and risks associated with HCV infection. More
research is needed to accurately and consistently define
appropriate cohorts when considering HCV prevalence
in SSA.
As with all studies, there are limitations to our study.
First, our study is externally limited by the lack of repre-
sentation across regions and cohorts, as well as among
children. Our multivariable meta-analysis findings (Fig. 3)
excluded children and focus on estimates across cohorts
and regions only among adults. Moreover, the lack of
available information on age distributions of the cohorts
studied make age-adjusted prevalence estimates, even
among the adult population, unattainable and unreliable.
Finally, we do not account for frequency of active, viremic
infection, due to limited data on this variable.
Conclusions
This meta-analysis offers a timely update of the burgeon-
ing HCV disease burden in SSA. Importantly, this report
highlights the stark differences in cohort representation
across regions among published reports, and emphasizes
the variability of HCV sero-prevalence by both region and
cohort. A large proportion of the global HCV burden
occurs in SSA, necessitating the need for more representa-
tive studies on the HCV epidemic across SSA.
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